Pharmepéna-Psychonautics: Human intranasal, sublingual and oral pharmacology of 5-methoxy-N,N-dimethyl-tryptamine.
Summarized are psychonautic bioassays (human self-experiments) of pharmepéna--crystalline 5-methoxy-N,N-dimethyltryptamine (5-MeO-DMT; O-Me-bufotenine), at times combined with crystalline beta-carbolines (harmaline or harmine). These substances were administered via intranasal, sublingual and oral routes, by way of pharmacological modeling of diverse South American shamanic inebriants (principally the snuffs epéna/nyakwana, prepared from barks of diverse species of Virola.) Intranasal, sublingual and oral psychoactivity of 5-MeO-DMT, and the 1967 Holmstedt-Lindgren hypothesis of the paricá-effect--intranasal potentiation of tryptamines by concomitant administration of monoamine-oxidase-inhibiting (MAOI) beta-carbolines from stems of Banisteriopsis caapi admixed with the snuffs--have been confirmed by some 17 psychonautic bioassays. Salient phytochemical and psychonautic literature is reviewed.
Ott
J
J
Phantastica, Barcelona, Spain.
D000281:Administration, Intranasal; D000284:Administration, Oral; D000286:Administration, Sublingual; D003469:Culture; D006213:Hallucinogens / Q000008:administration & dosage / Q000494:pharmacology*; D006246:Harmaline / Q000008:administration & dosage / Q000494:pharmacology; D006247:Harmine / Q000008:administration & dosage / Q000494:pharmacology; D006801:Humans; D008732:Methoxydimethyltryptamines / Q000008:administration & dosage / Q000494:pharmacology*; D008996:Monoamine Oxidase Inhibitors / Q000494:pharmacology
D006213:Hallucinogens; D008732:Methoxydimethyltryptamines; D008996:Monoamine Oxidase Inhibitors; D006247:Harmine; D006246:Harmaline